Accipiter Biosciences Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Accipiter Biosciences Inc. - overview
Established
2023
Location
Seattle, WA, US
Primary Industry
Biotechnology
About
Based in Washington, US, and founded in 2023 by co-founders Matthew Bick, Javier Castellanos, and Hector Rincon, Accipiter Biosciences operates as a biotechnology company. In November 2025 Accipiter Biosciences raised USD 12. 7 million in seed funding co-led by investors Takeda Digital Ventures and Flying Fish, with participation from other investors Columbus Venture Partners, Cercano Management, Washington Research Foundation, Alexandria Venture Investments, Pack Ventures, and Argonautic Ventures. Accipiter Biosciences specializes in the development of next-generation multifunctional biologics, by utilizing advanced computational methods.
The company's expertise lies in designing multifunctional biologics that could potentially revolutionize the treatment landscape across various therapeutic areas.
Current Investors
Alexandria Venture Investments, WRF Capital, Flying Fish
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Healthcare IT, Analytics & Performance Software, Medical Software
Website
www.accipiterbio.com
Verticals
Artificial Intelligence
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.